The last day of operation for Hertfordshire and West Essex ICB was 31 March 2026. The information on this website has not been updated since 31 March 2026. The legacy policies, prescribing recommendations and pathways can be accessed on this website. Find out more

Find clinical documents

or

Document type:
RAG rating:question mark
Output type:
Medicine / Guideline Indication RAG rating Document type Place
Adalimumab Uveitis - non-infectious (NHSE) Red NICE technology appraisal Hertfordshire and West Essex ICB
Aflibercept 2mg Wet AMD Red Prescribing guideline Hertfordshire and West Essex ICB
Aflibercept 2mg biosimilar Choroidal neovascularisation (CNV) assoictaed with pathological myopia Red Decision document Hertfordshire and West Essex ICB
Aflibercept 2mg biosimilar Diabetic macular oedema Red Prescribing pathway Hertfordshire and West Essex ICB
Aflibercept 2mg biosimilar Macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) Red Decision document Hertfordshire and West Essex ICB
Aflibercept 8mg Diabetic macular oedema Red Prescribing pathway Hertfordshire and West Essex ICB
Aflibercept 8mg wet AMD Red Prescribing guideline Hertfordshire and West Essex ICB
Bevacizumab (Avastin) Wet AMD Red Prescribing guideline Hertfordshire and West Essex ICB
Bevacizumab gamma (Lytenava) Wet AMD Red NICE technology appraisal Hertfordshire and West Essex ICB
Biologic and Biosimilar Medicines Where indicated n/a Patient information Hertfordshire and West Essex ICB
Blepharoplasty and Brow Lift n/a Clinical policy Hertfordshire and West Essex ICB
Blepharoplasty and Brow Lift Prior Approval Form n/a Prior approval form Hertfordshire and West Essex ICB
Brolucizumab Diabetic macular oedema Red Prescribing pathway Hertfordshire and West Essex ICB
Brolucizumab Wet AMD Red Prescribing guideline Hertfordshire and West Essex ICB
Cataract Surgery n/a Clinical policy Hertfordshire and West Essex ICB
Chalazia (meibomian cysts) removal n/a Clinical policy Hertfordshire and West Essex ICB
Chalazia Prior Approval Form n/a Prior approval form Hertfordshire and West Essex ICB
Choroidal neovascularisation (CNV) associated with pathological myopia Choroidal neovascularisation (CNV) assoictaed with pathological myopia Red Decision document Hertfordshire and West Essex ICB
Ciclosporin eye drops Dry eye disease that has not improved despite treatment with artificial tears Amber initiation NICE technology appraisal Hertfordshire and West Essex ICB
Cosopt eye drops to generic-switch-letter Glaucoma, raised IOP n/a Patient information Hertfordshire and West Essex ICB
Dexamethasone intravitral implant Macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) Red Prescribing guideline Hertfordshire and West Essex ICB
Dexamethasone intravitreal implant Uveitis - non-infectious Red NICE technology appraisal Hertfordshire and West Essex ICB
Dexamethasone intravitreal implant Diabetic macular oedema Red Prescribing pathway Hertfordshire and West Essex ICB
Diabetic Macular Oedema Diabetic Macular Oedema Red Prescribing pathway Hertfordshire and West Essex ICB
Dry Eye Disease Dry eye disease n/a Prescribing guideline Hertfordshire and West Essex ICB
Dry eye lubrication drops & gels – frequently asked questions. Dry eye disease n/a Patient information Hertfordshire and West Essex ICB
Dysthyroid Eye Disease n/a Clinical policy Hertfordshire and West Essex ICB
Faricimab Diabetic macular oedema Red Prescribing pathway Hertfordshire and West Essex ICB
Faricimab Macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) Red Prescribing guideline Hertfordshire and West Essex ICB
Faricimab Wet AMD Red Prescribing guideline Hertfordshire and West Essex ICB
Fluocinolone intravitreal implant Diabetic macular oedema Red Prescribing pathway Hertfordshire and West Essex ICB
Fluocinolone intravitreal implant Uveitis - non-infectious Red NICE technology appraisal Hertfordshire and West Essex ICB
Latanoprost–netarsudil Glaucoma (primary open-angle) or ocular hypertension Amber initiation NICE technology appraisal Hertfordshire and West Essex ICB
Lutein and Antioxidants Eye Supplements for AMD Double Red Prescribing guideline Hertfordshire and West Essex ICB
Lutein and Antioxidants Patient Information Leaflet Eye Supplements for AMD n/a Patient information Hertfordshire and West Essex ICB
Macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) Macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) Red Prescribing guideline Hertfordshire and West Essex ICB
Mercaptamine Corneal cystine deposits (NHSE) Red n/a Hertfordshire and West Essex ICB
Ocriplasmin Vitreomacular traction Double Red NICE technology appraisal Hertfordshire and West Essex ICB
Ranibizumab Diabetic retinopathy Double Red NICE technology appraisal Hertfordshire and West Essex ICB
Ranibizumab Choroidal neovascularisation (CNV) associated with pathological myopia Red Decision document Hertfordshire and West Essex ICB
Ranibizumab Wet AMD Red Prescribing guideline Hertfordshire and West Essex ICB
Ranibizumab biosimilar Diabetic macular oedema Red Prescribing pathway Hertfordshire and West Essex ICB
Ranibizumab biosimilar Macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) Red Prescribing guideline Hertfordshire and West Essex ICB
Wet AMD Wet AMD Red Prescribing guideline Hertfordshire and West Essex ICB